OOIR: Observatory of International Research

Papers

(The TQCC of Immunotherapy is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study	84
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study	68
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia	47
Alemtuzumab-Induced Red Cell Aplasia And Other Immune Cytopenias: Not So Â€˜Pureâ€™	37
Imaging of brain metastases treated with immune checkpoint inhibitors	34
An Update on the Adalimumab Biosimilar Landscape Following Approval of the First High-Concentration Biosimilar	33
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma	30
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study	28
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma	27
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas	26
Postvaccination immune-mediated hepatitis: what do we really know?	22
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158	21
Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?	18
Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis	17
Treatment and Overall Survival Among Anti-PD-1-Exposed Advanced Melanoma Patients with Evidence of Disease Progression	17
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data	17
Immunotherapy for Gastric Cancer: A 2021 Update	17
Subcutaneous Immunoglobulin Use in Immunoglobulin-Naive Patients with Primary Immunodeficiency: A Systematic Review	16
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors	15
Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy	15
Cost–Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer	14
What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?	14
Nivolumab induced discolouration of the tongue: a case report	14
Safety and Efficacy of Mutant Neoantigen-Specific T-Cell Treatment Combined Anti-Pd-1 Therapy in Stage Iv Solid Tumors	14
Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis	14

4-1BB Antibody Enhances Cytotoxic Activity of Natural Killer Cells Against Prostate Cancer Cells Via NKG2D Agonist Combined with IL-27	14
Assessing Pd-L1 Status in Mrcc Treated with First-Line Immune-Based Combinations: A Meta-Analysis	14
Anlotinib Succeeded in Rescue Therapy For Hyperprogression Induced by Immune Checkpoint Inhibitors: A Case Report	14
Cancer Immunotherapy Via Stem Cell-Derived NK Cells	13
Efficacy of mIte Allergen Immunotherapy in Allergic Rhinitis and the Immune Synergistic Effect on Cross-Allergens	13
Durvalumab after Chemoradiotherapy in Patients with Stage III Non-Small-Cell Lung Cancer: Real-World Outcomes Versus Clinical Trial Results	13
Adherence, persistence and treatment switching in psoriasis	13
Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors	13
Secukinumab in the treatment of psoriatic arthritis or ankylosing spondyloarthritis with multiple sclerosis: a case series with literature review	13
Emerging Advances in Nanomedicine for Breast Cancer Immunotherapy: Opportunities and Challenges	12
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review	12
Immune-Checkpoint Inhibitors in Renal Transplanted Patients Affected by Melanoma: A Systematic Review	12
Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins	12
Durvalumab in Advanced Cholangiocarcinoma: Is Someone Knocking Down the Door?	12
Lessons From the Diagnosis and Treatment of Severe Immune Checkpoint Inhibitor-Associated Pneumonia: A Case Report	12
Infection Rates and Tolerability of Three Different Immunoglobulin Administration Modalities in Patients with Primary Immunodeficiency Diseases	11
Deucravacitinib in Moderate-To-Severe Psoriasis	11
Immune Checkpoint Inhibitors in Cholangiocarcinoma	11
Current Immunosuppression Strategies in Pediatric Heart Transplant	11
Germinal center immune dynamics: challenges for effective vaccination in the elderly	11
Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma	11
SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma	10
Liquid biopsy for guiding breast cancer immunotherapy	10
Human Growth Hormone Supplement Promotes Human Lymphohematopoietic Cell Reconstitution in Immunodeficient Mice	10
A Summertime Pause in Immunoglobulin Replacement Therapy: A Prospective Real-World Analysis	10
Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics	10
Applications and Current Challenges of Chimeric Antigen Receptor T Cells in Treating High-Grade Gliomas in Adult and Pediatric Populations	10
Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature	10
Treatment of Plaque Psoriasis with Deucravacitinib (POETYK PSO-1 Study): A Plain Language Summary	10
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management	10
Integrase inhibitors: current protagonists in antiretroviral therapy	10
Immune Checkpoint Inhibitor-Induced Autoimmune Encephalitis in Metastatic Squamous Cell Lung Cancer	10
Poor Response to Sintilimab Plus Chemotherapy in a Pulmonary Epithelioid Hemangioendothelioma Patient: A Case Report	10
Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens	9
Effectiveness of COVID-19 Vaccines Against Omicron Variant	9
Steroid-Dependent Polyarthritis Induced by Immune Checkpoint Inhibitor Therapy Successfully Treated with Bimekizumab	9
A Meta-Analysis of Application of Pd-1/Pd-L1 Inhibitor-Based Immunotherapy in Unresectable Locally Advanced Triple-Negative Breast Cancer	9
Therapeutic Intervention of Glioma with the Novel Antineoplastic Agent T11TS: The Story so Far	9
Immune-Related Gigantomastia: A Case Study	9
Abrocitinib for the Treatment of Atopic Dermatitis	8
Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis	8
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma	8
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis	8
Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib	8
Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs	8
Ipilimumab and Nivolumab: The ‘New Kid on the Block’ in Advanced Angiosarcoma	8
Immune Checkpoint Inhibitors in Lung Tumors with Rare Histologies and Other Thoracic Malignancies	8
TOPAZ-1: A New Standard of Care for Advanced Biliary Tract Cancers?	8
Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report	8
Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis	8

Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy	7
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab	7
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?	7
Intratumoral Delivery of Immune Therapy and Gene Therapy: The Next Era for Cancer Therapy	7
Long-Term Response to Camrelizumab in a Pretreated Metastatic Mixed Testicular Germ-Cell Tumor Patient with Co-Mutations in DNA Damage-Repair Genes	7
An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy	7
Ocular Toxicities in Chimeric Antigen Receptor T-Cell Therapy: A Real-World Study Leveraging FAERS Database	7
Treatment patterns and outcomes in melanoma brain metastasis: exploring immune-related adverse events and survival	7
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)	7
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma	7
Late-Onset Toxicities of Monoclonal Antibodies in Cancer Patients	7
Pembrolizumab in an HIV-infected patient with glioblastoma	7
Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease	7
Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events	7
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China	7
Combination of Methotrexate with Oral Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Systematic Review	7
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study	7
Indirect Comparison of Pembrolizumab Monotherapy Versus Nivolumab + Ipilimumab in First-Line Metastatic Lung Cancer	7
Impact of Helicobacter Pylori Infection on The Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis	7
Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease	6
Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors	6
Fractional Exhaled Nitric Oxide in Checkpoint Inhibitor Pneumonitis: A Case Report and Literature Review	6
Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis	6
A New Perspective on The Potential Application of Ripk1 in the Treatment of Sepsis	6
The Effect of Low-Dose Chemotherapy on the Tumor Microenvironment and its Antitumor Activity Combined with Anti-PD-1 Antibody	6
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases	6
Cutaneous Metastases at the Sites of Pembrolizumab-Induced Bullous Pemphigoid Lesions in a Patient with Melanoma	6
Pathological Findings Directing Immunotherapy in Renal Cell Carcinomas	6
Immunotherapies for prevention and treatment of type 1 diabetes	6
Could senescent cells be the prescription for therapeutic cancer vaccines?	6
Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary	6
Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy	6
Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literature	6
An Unusual Case of Immune-Related Gastritis in One Patient Receiving Toripalimab Therapy	6
Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study	6
Allogeneic CAR-T cells for cancer immunotherapy	6
Indications and Effects of Biological Agents in the Treatment of Noninfectious Uveitis	6
The Development of Litifilimab (BIIB 059) for Cutaneous and Systemic Lupus Erythematosus	6
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer	6
Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates	6
Moving Beyond Single-Agent Checkpoint Inhibition in Biliary Tract Cancers: What is the Next Frontier?	6
Pegcetacoplan Treatment for Geographic Atrophy Due to Age-Related Macular Degeneration: A Plain Language Summary of the FILLY Study	5
Infrequent Liver Injury from Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma	5
Pd-1/L1 Inhibitors May Increase the Risk of Pericardial Disease in Non-Small-Cell Lung Cancer Patients: A Meta-Analysis and Systematic Review	5
A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis	5
Treatment of EAE Mice with Treg, G-MDSC and IL-2: a New Insight into Cell Therapy for Multiple Sclerosis	5
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study	5
Tsunami of Immunotherapies in the Management of Esophageal Cancer	5
Cemiplimab-Induced Cytokine-Release Syndrome: Second Case Reported and Review of The Literature	5
Real-World Study: Drug Reduction in Children With Allergic Rhinitis and Asthma Receiving Immunotherapy	5
Plain language summary of disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT	5
Peripheral Blood Eosinophil Count is Associated with Response to Chemoimmunotherapy in Metastatic Triple-Negative Breast Cancer	5
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations	5
A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents	5
Safety and Effectiveness of a 300 IR House Dust Mite Sublingual Tablet: Descriptive 4-Year Final Analysis of a Post-Marketing Surveillance in Japan	5
Neoadjuvant Immunochemotherapy in the Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: A Systematic Review	5
Peptide–MHC Complexes: Dressing up to Manipulate T Cells Against Autoimmunity and Cancer	5
Radiation and Resolve: Unlocking the Synergistic Potential of Radioimmunotherapy in Advanced Lung Cancer Management	5
Bimekizumab for The Treatment of Psoriasis	5
Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review	5
The potential of phytomedicines to optimize CAR-T cell therapy in cancer	5
The Use of Dostarlimab, a Safe and Efficient Monotherapy in Msi-H Rectal Cancer Patients, an Alternative to Surgery	5
A CD123-Specific Chimeric Antigen Receptor Augments Anti-Acute Myeloid Leukemia Activity of Vγ9Vδ2 T Cells	5
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy	5
ICAM2 is Related to Good Prognosis in Dendritic Cell Immunotherapy for Cancer	5
Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy	5
Oncolytic Viruses in Lung Cancer Treatment: A Review Article	5
Amalgamation of Nanotechnology with Chicken IgY to Enrich Therapeutic and Diagnostic Applications: A Systematic Review	5
A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement	5
Efficacy of Long-Term Repeated Rituximab Treatment in Refractory Phospholipase A2 Receptor-Antibody-Related Membranous Nephropathy	5
Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial	5
Summary of Certolizumab Pegol in Psoriasis Including Structural Features, Pharmacokinetics and Treatment	5